The reverse ADS split is a routine administrative event with no fundamental impact. Monitor for any subsequent capital markets activity (e.g., equity offering) that may follow the ratio adjustment, as reverse splits often precede such actions.
Price Chart
Executive Summary
Biodexa Pharmaceuticals announced a mandatory ratio change for its American Depositary Shares (ADSs), effective as a 1-for-8 reverse ADS split, with the new ratio of 1 ADS representing 400 ordinary shares (up from 1 ADS representing 50 ordinary shares). The change is administrative and does not affect the underlying ordinary shares or the company's fundamentals.
Key Facts
- ADS ratio changes from 1 ADS : 50 ordinary shares to 1 ADS : 400 ordinary shares, effective October 26, 2026.
- ADS holders must surrender 8 old ADSs to receive 1 new ADS (New CUSIP: 59564R864).
- No fractional ADSs will be issued; aggregate fractions will be sold and proceeds distributed to holders.
- Ordinary shares are unaffected by the ratio change.
- JPMorgan Chase Bank, N.A. is the depositary and will handle the exchange.
Financial Impact
No financial impact; the ratio change is a mechanical adjustment to the ADS-to-ordinary-share ratio with no change to the company's equity or cash position.
Risk Factors
- Reverse ADS splits can be a precursor to a dilutive equity offering, which would pressure the stock.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001214659-26-012706 |
| Document: 0001214659-26-012706-index-headers.html | 0001214659-26-012706 |
| Document: 0001214659-26-012706-index.html | 0001214659-26-012706 |
| Document: 0001214659-26-012706.txt | 0001214659-26-012706 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | 6-K | $0.4849 | awaiting T+20 | — | $3.55 (+632.11%) |
Oct 8, 2026 18d ago | 6-K | $0.4602 | awaiting T+20 | — | $3.55 (+671.40%) |
Oct 1, 2026 26d ago | EFFECT | $0.6326 | awaiting T+20 | — | $3.55 (−461.18%) |
Sep 24, 2026 4w ago | F-1 | $0.6750 $0.4140 | ▲ +38.67% | ▲ +38.25% | $3.55 (−425.93%) |
Sep 15, 2026 6w ago | 6-K | $1.33 $0.3502 | ▼ −73.67% | ▼ −76.65% | $3.55 (+166.92%) |
Sep 11, 2026 6w ago | 6-K | $1.12 $0.3832 | ▲ +65.79% | ▲ +68.05% | $3.55 (−216.96%) |
Aug 4, 2026 12w ago | EFFECT | $11.92 $6.25 | ▲ +47.58% | ▲ +46.35% | $3.55 (+70.22%) |
Jun 30, 2026 16w ago | 6-K | $3.00 $1.45 | ▼ −51.83% | ▼ −49.65% | $3.55 (+18.33%) |
Jun 30, 2026 17w ago | 6-K | $2.91 $1.45 | ▲ +50.34% | ▲ +48.03% | $3.55 (−21.99%) |
Jun 17, 2026 18w ago | 6-K | $3.06 $2.13 | ▼ −30.39% | ▼ −30.93% | $3.55 (+16.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers